Skip to Content

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

The MAGNITUDE study highlights the importance of testing for HRR gene alterations in patients with metastatic castration-resistant prostate cancer treated with niraparib, abiraterone acetate and prednisone, as first-line therapy. In this MEDtalk Dr. Kim Chi, medical oncologist, presents results from the study and gives his perspective on the treatment as first-line therapy for this group of patients.

Kim Nguyen Chi

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top